Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Glaxo makes $1.0 million payment, starts phase 2 studies of oral platelet drug
March 10th, 2005
Ligand Pharmaceuticals Incorporated (LGND) announced that the company has earned a $1 million milestone payment from GlaxoSmithKline (GSK) with that company's commencement of phase 2 trials of SB-497115, an oral, small molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor that promotes growth and production of blood platelets. If the drug ultimately is approved and marketed, Ligand could receive double-digit royalties on product sales. Thrombocytopenia (decreased platelet count) is a common side effect of many types of chemotherapy and can lead to uncontrolled bleeding, thus representing a significant problem in the...
Source: Women's Health Weekly (2005-03-10)
|
